KOSPIChemicals285130

SK Chemicals

₩38,150 0.00%2026-11-18 close
Market Cap
₩659.9B
Turnover
₩1.6B
Volume
40K
Shares out.
17.3M
PER
72.9×
PBR
0.3×
EPS
₩547
Dividend Yield
2.89%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩1,150 per share · Prices as of the 2026-11-18 close

01

Report overview

Core Chemicals Margins Soften as Subsidiary Losses Narrow

Profitability in the core chemicals business has weakened, but narrower losses at subsidiary SK bioscience pushed consolidated operating profit into the black in Q2 2026 and higher again in Q3.

  1. 1

    Consolidated operating profit for Q3 2026 was KRW 33.6 billion, up 115.6% from a year earlier. Standalone operating profit in a preliminary filing dated November 9, 2026 fell 45.0% to KRW 16.4 billion, so the gain came from subsidiaries.

  2. 2

    Subsidiary SK bioscience posted a Q3 2026 operating loss of KRW 11.2 billion, down from KRW 19.4 billion a year earlier, and its narrower loss is central to the consolidated result.

  3. 3

    On an annual basis, the company posted operating losses in both 2024 and 2025. Revenue of KRW 2.37 trillion in 2025 was the largest of 2022 to 2025.

  4. 4

    The company set a 2030 target of KRW 50 billion in pharmaceutical operating profit at its CEO Investor Day in around October 2026, with in-licensed internal medicine products and proprietary combination drugs as the main levers.

  5. 5

    Samsung Securities said in a November 10, 2026 report that it lowered its target price to KRW 64,000 from KRW 68,000 while keeping its Buy rating.

02

Business structure

SK Chemicals operates a green chemicals unit built around specialty materials such as copolyester and monomers, a pharmaceutical unit, and consolidated subsidiaries.

In Q3 2026, the copolyester and monomer business in the green chemicals unit posted revenue of KRW 237.5 billion, up 13.9% year on year, while operating profit fell 34.8% to KRW 22.4 billion.

The company positions its copolyester made partly from recycled waste plastic, along with functional materials, as specialty products, and is expanding sales into higher-value uses such as cosmetic containers.

The pharmaceutical unit recorded revenue of KRW 139.2 billion and operating profit of KRW 9.7 billion in the same quarter, led by arthritis drug Joins and circulation drug Ginexin.

Subsidiary SK bioscience reported Q3 2026 revenue of KRW 182.4 billion and an operating loss of KRW 11.2 billion, helped by varicella vaccine sales and higher customer revenue at its German CDMO subsidiary IDT Biologika.

A cogeneration plant in Ulsan, held by a utility subsidiary that began commercial operation in November 2025, also added to consolidated revenue. A 2025 Kiwoom Securities report viewed the copolyester market as one with limited new entrants and described CHDM supply as split between SK Chemicals and Eastman.

The same report cited DMT-based feedstock, downstream integration and specialized equipment as barriers to entry. Consolidated results therefore move with both the chemicals and pharmaceutical core and the swings of the bio and utility subsidiaries.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩609.9B₩15.6B2.6%
2025Q4₩621.8B-₩39.1B−6.3%
2026Q1₩655.9B-₩18.9B−2.9%
2026Q2₩745.1B₩32.3B4.3%
2026Q3₩740.8B₩33.6B4.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩1.8T₩230.5B₩191.3B12.6%8.9%45.7%
2023₩1.7T₩83.3B₩39.9B4.8%1.9%55.4%
2024₩1.7T-₩45.2B₩8.8B−2.6%0.4%77.0%
2025₩2.4T-₩200M₩44.6B0.0%2.0%93.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

Annual revenue fell from KRW 1.83 trillion in 2022 to KRW 1.74 trillion in 2024 before rising 36.2% to KRW 2.37 trillion in 2025. The largest year of 2022 to 2025 was 2025, and the smallest was 2024.

Operating profit fell 63.9% from KRW 230.5 billion in 2022 to KRW 83.3 billion in 2023, and the company swung to an operating loss of KRW 45.2 billion in 2024. The 2025 operating loss of KRW 207 million narrowed from the prior year, and the company posted losses in both 2024 and 2025.

The operating margin slid from 12.6% in 2022 to 4.8% in 2023, -2.6% in 2024 and -0.0% in 2025, so the largest revenue year did not restore margin. Net income attributable to controlling shareholders bottomed at KRW 8.84 billion in 2024 and rose 405.1% to KRW 44.6 billion in 2025.

Net income including non-controlling interests was KRW 27.3 billion in 2025, and the gap between the two figures comes from non-controlling interests. The debt ratio climbed from 45.7% in 2022 to 93.8% in 2025, with total liabilities of KRW 2.95 trillion against total equity of KRW 3.14 trillion at year-end 2025.

Operating cash flow moved from -KRW 89.3 billion in 2024 to KRW 235.9 billion in 2025. On a quarterly basis, an operating loss of KRW 39.1 billion in Q4 2025 narrowed to KRW 18.9 billion in Q1 2026, and Q2 2026 swung to operating profit of KRW 32.3 billion.

Q3 2026 operating profit was KRW 33.6 billion, up 3.8% from the prior quarter, with net income attributable to controlling shareholders of KRW 46.6 billion, while the last four quarters total only KRW 11 billion.

Standalone operating profit for Q3 2026 was KRW 16.4 billion in a preliminary filing, down 45.0%, which shows that the consolidated profit depends on improvement at subsidiaries.

05

Industry analysis

In its Q3 2026 results, the company cited higher raw material prices, a weaker won and oil price swings as headwinds across the chemicals industry. Samsung Securities attributed the weaker chemicals profitability to lower sales volumes after the end of a Middle East-driven demand boost, along with higher costs.

The company also pointed to slower global demand and port congestion as burdens on sales volumes. Reports on the Q3 results repeatedly noted that the company stayed profitable despite a sluggish domestic petrochemical market.

A 2025 Kiwoom Securities report described the copolyester market as centered on specialty materials that are differentiated from commodity products.

The same report judged that Chinese producers find it hard to expand higher-value copolyester supply and that China's policy push toward advanced materials is unlikely to translate into much new capacity.

The company sees tighter global safety regulation as an opportunity to widen demand for higher-value materials such as copolyester and functional materials.

The company explains its profitability through specialty material competitiveness and stable pharmaceutical sales, and this is the company's own view, so the timing of an industry-wide demand recovery should be checked against independent data.

06

Outlook

The company said it plans to keep its copolyester demand base in Q4 2026 while broadening its portfolio around higher-value materials. It intends to strengthen its push into markets for cosmetic containers, medical materials, recycled materials and functional materials.

A company official said it will raise cost competitiveness in its core business and expand sales of higher-value products. In pharmaceuticals, the company withdrew a review of a sale in 2024 and grew its revenue base through in-licensed products, and it completed three in-licensing deals in internal medicine.

It is also running five or more short-term R&D projects focused on combination drugs. The 2030 target of KRW 50 billion in pharmaceutical operating profit was presented in the 2026 CEO Investor Day materials.

Subsidiary SK bioscience posted Q3 2026 revenue of KRW 182.4 billion and an operating loss of KRW 11.2 billion, and whether its losses keep narrowing will be central to consolidated results.

Samsung Securities said in a November 10, 2026 report that it cut its 2027 EBITDA estimate by 21%, to KRW 276 billion from KRW 350 billion, to reflect weaker chemicals profitability. The same report said it expects the company to strengthen shareholder value measures to draw out the value of its assets.

The next checkpoints are the confirmed annual results in the 2026 annual report, the Q1 2027 earnings release, and the quarterly profit trend at SK bioscience.

07

Valuation

PER
72.9×
PBR
0.3×
ROE
0.5%
EPS
₩547
BPS
₩126,290
Dividend per share
₩1,150

Splitting valuation into an earnings lens and an asset lens makes the factual comparison clearer. On earnings, the last four quarters add up to only KRW 11 billion of net income attributable to controlling shareholders, so the multiple on earnings is high by construction.

The earnings base has shrunk from KRW 191.3 billion in 2022 to KRW 44.6 billion in 2025, and the move to operating profit in Q3 2026 points toward a recovery in that base.

On assets, the share price sits in a low range relative to net asset value, measured against controlling shareholders' equity of KRW 2.26 trillion at year-end 2025. Samsung Securities said it judges that the company's asset value is reflected too low in the share price.

On the other hand, the debt ratio rose to 93.8% by 2025 from 45.7% in 2022, so the asset-based reading should be checked alongside the capital structure. Whether dividends hold up through earnings swings can be checked in the dividend items of the annual report.

Share price multiples move with the price, so the direction of change in earnings and net assets is the reference point for reading them.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Consolidated profit back in the black

Consolidated operating profit turned positive at KRW 32.3 billion in Q2 2026 and reached KRW 33.6 billion in Q3, up 115.6% year on year. Subsidiary SK bioscience cut its operating loss to KRW 11.2 billion from KRW 19.4 billion a year earlier, which was reported as the direct driver of the consolidated gain.

The evidence that subsidiary improvement can partly offset the weaker core chemicals business is the main positive.

A target for pharmaceutical growth

The pharmaceutical unit posted Q3 2026 revenue of KRW 139.2 billion and operating profit of KRW 9.7 billion, both slightly higher than a year earlier.

The company is targeting KRW 50 billion in pharmaceutical operating profit by 2030 and widening its internal medicine chronic-disease range and proprietary combination drugs. The strategy of growing through in-licensed products after withdrawing a sale review in 2024 is the basis of the bullish case.

Asset value and shareholder return expectations

Samsung Securities said it judges that the share price reflects asset value too low, and that it expects stronger shareholder value strategies. The same report pointed to a low price-to-book level.

A 2025 Kiwoom Securities report cited expanding China sales of higher-value copolyester and high entry barriers as medium-term profit drivers.

09

Bear factors

Weaker profitability in the core chemicals business

Standalone operating profit for Q3 2026 fell 45.0% to KRW 16.4 billion. The copolyester and monomer business posted operating profit of KRW 22.4 billion, down 34.8%, as lower sales volumes, higher raw material costs and currency effects overlapped.

Weaker profitability in the main chemicals unit makes consolidated profit more dependent on subsidiaries, which is the core of the bearish case.

Strength of the disclosed results

The company posted operating losses in both 2024 and 2025, and the 2025 operating margin was -0.0%. The debt ratio rose from 45.7% in 2022 to 93.8% in 2025. Net income attributable to controlling shareholders over the last four quarters totals only KRW 11 billion, a thin earnings base that supports the bearish view.

Dependence on subsidiaries and a lower target price

Consolidated results swing sharply with subsidiary profits, as shown by the Q1 2026 consolidated operating loss of KRW 18.9 billion. Samsung Securities said in a November 10, 2026 report that it cut its 2027 EBITDA estimate by 21%.

In the same November 10, 2026 report, Samsung Securities lowered its target price to KRW 64,000 from KRW 68,000.

10

Risk factors

Subsidiary earnings volatility

Consolidated operating profit depends heavily on vaccine and CDMO sales at SK bioscience and on the size of its losses. As the Q1 2026 consolidated operating loss of KRW 18.9 billion shows, a deterioration at subsidiaries can push consolidated results into the red even when the core business is profitable. Subsidiary results change from quarter to quarter with customer orders and production efficiency.

Chemicals cycle, raw materials and currency

Higher raw material prices, a weaker won and oil price swings weighed on chemicals profitability at the same time. The fading of the Middle East-driven demand boost, which reduced sales volumes, shows the risk in the demand cycle.

If Chinese supply growth and weaker global demand persist, the effect of a higher-value product mix may be limited.

Capital structure and earnings base

The debt ratio climbed from 45.7% in 2022 to 93.8% in 2025, with total liabilities of KRW 2.95 trillion at year-end 2025. Operating cash flow swung from -KRW 89.3 billion in 2024 to KRW 235.9 billion in 2025, a large year-to-year change.

Net income attributable to controlling shareholders of KRW 11 billion over the last four quarters indicates limited earnings cushion.

11

What to watch next

  1. Early 2027 (timing of the annual preliminary results depends on the company's disclosure schedule)

    Q4 2026 and full-year preliminary results. Q4 consolidated operating profit will show whether SK bioscience turns profitable and whether the chemicals business recovers.

  2. Late March 2027 (annual report filing deadline)

    The 2026 annual report. Confirmed full-year results, the Q4 2026 figures, the debt ratio and operating cash flow are fixed in the periodic report.

  3. Around May 2027 (the Q1 2026 preliminary results were disclosed on May 8, 2026)

    Q1 2027 results. This is where progress toward the KRW 50 billion 2030 pharmaceutical profit target and the pace of volume and cost recovery in chemicals can be checked.

12

Overall view

SK Chemicals posted consolidated operating profit of KRW 33.6 billion in Q3 2026, up 115.6% year on year, continuing its profitable run. Standalone operating profit, however, fell 45.0% to KRW 16.4 billion, and the copolyester and monomer business's operating profit dropped 34.8%.

Much of the consolidated improvement came from narrower losses at SK bioscience, so subsidiary results largely determine the consolidated outcome. On disclosed annual results, the company posted operating losses in both 2024 and 2025, and the debt ratio rose to 93.8% in 2025.

Net income attributable to controlling shareholders over the last four quarters totals KRW 11 billion, a thin earnings base. The pharmaceutical unit has a growth axis built on a 2030 target of KRW 50 billion in operating profit and an expanding internal medicine in-licensing program.

Samsung Securities cut its target price to reflect weaker chemicals profitability but kept its Buy rating.

The timing of a chemicals demand recovery and of SK bioscience's return to profit are the variables that will shape the direction of results, and the next checkpoints are the 2026 annual report, the Q1 2027 earnings release and the quarterly profit trend at SK bioscience.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. vegannews.co.kr
  2. dailian.co.kr
  3. lcnews.co.kr
  4. view.asiae.co.kr
  5. newspim.com
  6. m-i.kr
  7. businesspost.co.kr
  8. g-enews.com
  9. etoday.co.kr
  10. kpanews.co.kr
  11. skchemicals.com
  12. intn.co.kr
  13. hankyung.com
  14. huffingtonpost.kr
  15. kndaily.co.kr
  16. finance.eduinfom.com
  17. medipana.com
  18. docdocdoc.co.kr

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis